| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Kastelein Johannes Jacob Pieter | Chief Scientific Officer, Director | C/O NEWAMSTERDAM PHARMA COMPANY N.V., GOOIMEER 2-35, NAARDEN, NETHERLANDS | /s/ Louise Kooij by Power of Attorney from Johannes Jacob Pieter Kastelein | 24 Feb 2026 | 0002000389 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | NAMS | Ordinary Shares | Sale | $514,220 | -14,692 | -15% | $35.00 | 84,289 | 20 Feb 2026 | Direct | F1 |
| transaction | NAMS | Ordinary Shares | Sale | $1,091,778 | -30,789 | -37% | $35.46 | 53,500 | 20 Feb 2026 | Direct | F2 |
| Id | Content |
|---|---|
| F1 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.24 to $35.23 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. |
| F2 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.24 to $35.86 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. |